TDAC on Nasdaq
Translational Development Acquisition Corp.
Blank check company, listed on Nasdaq (TDAC). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerTDAC on Nasdaq1
- IndustryBlank Checks1
- HeadquartersNew York, New York1
- Business address52 E 83Rd St., New York, Ny 100283
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
The registration statement (File No. 333-282763) (the “Registration Statement”) for our initial public offering was declared effective on December 20, 2024 (the “IPO”). On December 24, 2024, we consummated the IPO of 17,250,000 units (the “Units”), which includes the full exercise of the underwriter’s over-allotment option. Each Unit consists of one Class A ordinary share (the “Ordinary Share”) and one-half of one redeemable warrant (the “Warrant”), each whole Warrant entitling the holder thereof to purchase one Ordinary Share for $11.50 per share. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $172,500,000.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative costs | $944.5K | $196.4K |
| Loss from operations | -$944.5K | -$196.4K |
| Dividends earned on marketable securities held in Trust Account | $7.3M | $125.3K |
| Total other income | $7.3M | $125.3K |
| Net income (loss) | $6.4M | -$71.0K |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $29.8K | $438.2K | |
| Prepaid expenses | $9.7K | $212.1K | |
| Total Current Assets | $39.5K | $650.2K | |
| Marketable securities held in Trust Account | $181.7M | $174.4M | |
| TOTAL ASSETS | $181.7M | $175.0M | |
| Accounts payable and accrued expenses | $162.3K | $16.2K | |
| Due to Sponsor | $106.8K | $2.0K | |
| Promissory note - related party | $200.0K | ||
| Accrued offering costs | $75.0K | $192.1K | |
| Total Current Liabilities | $544.1K | $210.3K | |
| Deferred underwriting fee | $6.0M | $6.0M | |
| TOTAL LIABILITIES | $6.6M | $6.2M | |
| Accumulated deficit | -$6.5M | -$5.6M | |
| Total Shareholders' Deficit | -$6.5M | -$5.6M | -$507.7K |
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit | $181.7M | $175.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $29.8K | $438.2K | |
| Prepaid expenses | $9.7K | $212.1K | |
| Total Current Assets | $39.5K | $650.2K | |
| Marketable securities held in Trust Account | $181.7M | $174.4M | |
| TOTAL ASSETS | $181.7M | $175.0M | |
| Accounts payable and accrued expenses | $162.3K | $16.2K | |
| Due to Sponsor | $106.8K | $2.0K | |
| Promissory note - related party | $200.0K | ||
| Accrued offering costs | $75.0K | $192.1K | |
| Total Current Liabilities | $544.1K | $210.3K | |
| Deferred underwriting fee | $6.0M | $6.0M | |
| TOTAL LIABILITIES | $6.6M | $6.2M | |
| Accumulated deficit | -$6.5M | -$5.6M | |
| Total Shareholders' Deficit | -$6.5M | -$5.6M | -$507.7K |
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders' Deficit | $181.7M | $175.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (loss) | $6.4M | -$71.0K |
| Payment of operation costs through promissory note | $4.7K | |
| Dividends earned on marketable securities held in Trust Account | -$7.3M | -$125.3K |
| Prepaid expenses | $202.4K | -$212.1K |
| Due to Sponsor | $104.8K | $2.0K |
| Accounts payable and accrued expenses | $29.0K | -$449.7K |
| Net cash used in operating activities | -$608.4K | -$851.4K |
| Investment of cash in Trust Account | -$174.2M | |
| Net cash used in investing activities | -$174.2M | |
| Proceeds from sale of Units, net of underwriting discounts paid | $169.1M | |
| Proceeds from sale of Private Placements Warrants | $7.1M | |
| Proceeds from promissory note - related party | $200.0K | $406.5K |
| Repayment of promissory note - related party | -$800.0K | |
| Payment of offering costs | -$218.9K | |
| Net cash provided by financing activities | $200.0K | $175.5M |
| Net Change in Cash | -$408.4K | $436.2K |
| Offering costs included in accrued offering costs | $495.9K | |
| Deferred offering costs paid through promissory note - related party | $41.2K | |
| Deferred underwriting fee | $6.0M | |
| Offering costs charged to additional paid-in capital | $756.1K |
No quarter-by-quarter statement was filed.
Compare Translational Development Acquisition Corp. with another company
Leadership
Who has led Translational Development Acquisition Corp., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerMichael B. Hoffman Dec 20, 2024 to now10
- ChairMichael B. Hoffman May 29, 2026 to now11
- Chief financial officerAvanindra Das Dec 20, 2024 to now12
Board members and other officers (4)
- Board memberChristopher Kenneth Jarratt Jan 6, 2025 to now13
- Board memberCurtis T. Keith Dec 20, 2024 to now14
- Board memberMatthew Kestenbaum Dec 20, 2024 to now15
- Board memberMichael B. Hoffman Dec 20, 2024 to now10
Timeline
- Dec 20, 2024New chief executive Michael B. Hoffman becomes CEO10
Filings
66 filings to the SEC since October 2021: 4 annual reports, 5 quarterly reports, 10 major events, 8 insider forms, 14 large holders, 25 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 12, 2026SCHEDULE 13G/A EDGAR
- Jul 27, 2026425 EDGAR
- Jul 27, 20268-K EDGAR
- Jul 16, 2026SCHEDULE 13G/A EDGAR
- Jul 8, 20268-K EDGAR
- Jun 23, 2026DEFA14A EDGAR
- Jun 23, 2026425 EDGAR
- Jun 23, 20268-K EDGAR
- Jun 18, 20268-K EDGAR
- Jun 12, 20268-K EDGAR
- Jun 2, 2026SCHEDULE 13G EDGAR
- May 29, 20264 OWNERSHIP DOCUMENT EDGAR
- May 28, 2026DEFA14A EDGAR
- May 27, 2026DEF 14A EDGAR
- May 27, 2026425 EDGAR
- May 27, 20268-K EDGAR
- May 15, 202610-Q EDGAR
The 66 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Linden Capital L.P.SCHEDULE 13G/A, 2 filings Jun 2, 2026 to Aug 14, 202616
- METEORA CAPITAL, LLCSCHEDULE 13G, 1 filing Aug 14, 202617
- Goldman SachsSCHEDULE 13G/A, 2 filings May 13, 2026 to Aug 12, 202618
- WOLVERINE ASSET MANAGEMENT LLCSCHEDULE 13G/A, 4 filings May 1, 2025 to Jul 16, 202619
- AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 14, 202520
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 14, 202521
- Magnetar Financial LLCSCHEDULE 13G, 1 filing Jan 29, 202522
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARMichael B. Hoffman, Chair
- 12
- 13
- 14SEC EDGARCurtis T. Keith, Board member
- 15SEC EDGARMatthew Kestenbaum, Board member
- 16
- 17
- 18
- 19
- 20
- 21
- 22